Abstract
When seriously ill patients for whom existing treatments are inadequate are invited to participate in clinical trials that offer a new treatment, should those persons be considered "vulnerable"? And if so, what additional protections should they be accorded? This article attempts to provide some answers.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have